Assessment of Biological factors
PreclinicalBiologic
Assessment of Biological factors is one of 50 biologic programs targeting Chronic pain. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
49
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
77 competitors in Chronic Pain
#DrugCompanyPhaseTrials
1Marinol
Jazz PharmaceuticalsApproved
Intuniv
PPromius Pharma, LLC
Approved
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Oxycontin
PProtega
Approved
Marcaine
IInnocoll
Approved
Sufenta
LLeaf Vertical Inc.
Approved
Decadron
AAspen Global Incorporated
Approved
Versed
CConrado Roberto Hoffmann Filho
Approved
Prilosec
DDexcel Pharma Technologies Ltd.
Approved
Minocin
TTriax
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Preclinical[1]
- Company
- QQueen Mary University of London